CN101822711B - 中药复方灌注液的制备方法及用途 - Google Patents
中药复方灌注液的制备方法及用途 Download PDFInfo
- Publication number
- CN101822711B CN101822711B CN201010183636A CN201010183636A CN101822711B CN 101822711 B CN101822711 B CN 101822711B CN 201010183636 A CN201010183636 A CN 201010183636A CN 201010183636 A CN201010183636 A CN 201010183636A CN 101822711 B CN101822711 B CN 101822711B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- adds
- traditional chinese
- purified water
- extracting solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 23
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003208 petroleum Substances 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 238000004108 freeze drying Methods 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 27
- 239000008213 purified water Substances 0.000 claims description 25
- 241000180649 Panax notoginseng Species 0.000 claims description 18
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 17
- 239000012567 medical material Substances 0.000 claims description 17
- 206010005003 Bladder cancer Diseases 0.000 claims description 14
- 239000003978 infusion fluid Substances 0.000 claims description 14
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 13
- 238000005516 engineering process Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 238000010791 quenching Methods 0.000 claims description 6
- 229940126678 chinese medicines Drugs 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 238000000247 postprecipitation Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000013049 sediment Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 16
- 230000002980 postoperative effect Effects 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 7
- 210000004881 tumor cell Anatomy 0.000 abstract description 7
- 206010052428 Wound Diseases 0.000 abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 abstract description 6
- 235000015162 Caesalpinia sappan Nutrition 0.000 abstract description 3
- 238000004140 cleaning Methods 0.000 abstract description 3
- 238000001035 drying Methods 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 238000002271 resection Methods 0.000 abstract description 3
- 244000131316 Panax pseudoginseng Species 0.000 abstract description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 241000209639 Biancaea sappan Species 0.000 abstract 2
- 238000009835 boiling Methods 0.000 abstract 1
- 238000005238 degreasing Methods 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 238000012423 maintenance Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000001665 lethal effect Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000010412 perfusion Effects 0.000 description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical group N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000035777 life prolongation Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000003443 bladder cell Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 244000306301 Caesalpinia sappan Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002574 cystoscopy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000013010 irrigating solution Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000009800 partial cystectomy Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 动物数开始/结束 | 给药剂量Mg.Kg-1×d | 平均生存天数(d) | 生命延长率(%) | P值 |
对照组 | 10/0 | 17.3±5.1 | |||
顺铂 | 10/1 | 2×6 | 38.6±9.6** | 123.12 | P<0.001 |
复方高 | 10/2 | 300×6 | 43.1±8.3** | 149.13 | P<0.001 |
复方中 | 10/0 | 200×6 | 39.4±6.7** | 127.75 | P<0.001 |
复方低 | 10/0 | 100×6 | 37.5±8.6** | 116.76 | P<0.001 |
组别 | 动物数开始/结束 | 给药剂量Mg.Kg-1×d | 平均生存天数(d) | 生命延长率(%) | P值 |
对照组 | 10/0 | 19.3±4.1** | |||
顺铂 | 10/0 | 2×6 | 40.7±6.1** | 111.98 | P<0.001 |
复方高 | 10/3 | 300×6 | 44.1±8.7** | 129.69 | P<0.001 |
复方中 | 10/0 | 200×6 | 37.1±6.9** | 93.23 | P<0.001 |
复方低 | 10/0 | 100×6 | 38.5±9.0** | 100.752 | P<0.001 |
初发组 | 36 | 27-79 | 0 | 1(1.7) | 1(1.7) | 2(3.4) |
复发组 | 23 | 41-81 | 1(1.7) | 3(5.1) | 2(3.4) | 6(10.17) |
合计 | 59 | 27-81 | 1(1.7) | 4(6.8) | 3(5.1) | 8(13.56) |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010183636A CN101822711B (zh) | 2010-05-22 | 2010-05-22 | 中药复方灌注液的制备方法及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010183636A CN101822711B (zh) | 2010-05-22 | 2010-05-22 | 中药复方灌注液的制备方法及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101822711A CN101822711A (zh) | 2010-09-08 |
CN101822711B true CN101822711B (zh) | 2012-10-24 |
Family
ID=42687014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010183636A Expired - Fee Related CN101822711B (zh) | 2010-05-22 | 2010-05-22 | 中药复方灌注液的制备方法及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101822711B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1422617A (zh) * | 2002-12-12 | 2003-06-11 | 上海中医药大学 | 全缘千里光碱脂质体凝胶剂及制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1105588A (zh) * | 1994-11-02 | 1995-07-26 | 范冬锁 | 抗癌中药必赐康胶囊及其制造方法 |
-
2010
- 2010-05-22 CN CN201010183636A patent/CN101822711B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1422617A (zh) * | 2002-12-12 | 2003-06-11 | 上海中医药大学 | 全缘千里光碱脂质体凝胶剂及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101822711A (zh) | 2010-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102302737B (zh) | 一种治疗胃癌的中药组合物 | |
CN105362340B (zh) | 一种治疗白血病的药物组合物及其制备方法 | |
KR20190124197A (ko) | 종양 치료용 한약 조성물 및 그 제조방법 및 응용 | |
CN101810646B (zh) | 一种从桑黄中提取抗病毒活性物质的方法 | |
CN106668041A (zh) | 重楼皂苷vi在制备抗肺癌药物中的应用 | |
CN1895337B (zh) | 党参黄芪组合物提高晚期肿瘤患者生存质量的制药用途 | |
CN102389559B (zh) | 一种中药组合物及其作为放疗增敏剂的应用 | |
CN101822711B (zh) | 中药复方灌注液的制备方法及用途 | |
CN102078600B (zh) | 抗癌复方灵芝组合物、其用途和包含其的药物组合物 | |
CN101011543B (zh) | 一种新的抗肿瘤药物组合物 | |
CN104096150B (zh) | 姜叶三七及其提取物在制备治疗和/或预防癌症药物的应用 | |
CN102423384B (zh) | 一种治疗肺癌的中药制剂及其制备方法 | |
CN102872385A (zh) | 一种治疗晚期胃癌的复方中药组合物及其制备方法和应用 | |
CN113209149A (zh) | 米托蒽醌与人参总皂苷联合用药在制备治疗胃癌药物中的应用 | |
CN100427099C (zh) | 能够有效治疗脑癌的胡桃楸多糖制剂及其制备方法 | |
CN100411663C (zh) | 复方中药抗癌散及其制备方法 | |
CN103191268B (zh) | 一种治疗肺癌的中药组合物 | |
CN102440994A (zh) | 灵芝酸g在肿瘤治疗中作为免疫增效剂和超抗原依赖的治疗药物的应用 | |
CN111544479B (zh) | 一种药物组合物在制备治疗癌症药物中的应用 | |
CN115400176B (zh) | 荔枝核提取物的制备方法和应用 | |
US20060039999A1 (en) | Pharmaceutical composition for inhibition of tumor growth or metastasis | |
CN111202818B (zh) | 一种中药组合物及其制备方法和应用 | |
CN102716382A (zh) | 一种治疗肺癌的中药组合物及其制备方法 | |
CN103495002B (zh) | 一种抗肿瘤的中药组合物及其制备方法和应用 | |
CN104473946A (zh) | 一种治疗白血病的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING XIMALAYA TECHNOLOGY DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: SHANXI PROVINCE TUMOR HOSPITAL Effective date: 20140526 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 030013 TAIYUAN, SHAANXI PROVINCE TO: 100039 HAIDIAN, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140526 Address after: 100039 room 83, 105 Fuxing Road, Beijing, Haidian District Patentee after: Beijing Himalayan science and Technology Development Co Ltd Address before: 030013 Taiyuan workers Street, No. 3, Shanxi Patentee before: Shanxi Province Tumor Hospital |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160701 Address after: 030032 Shanxi Province, Taiyuan City District North East ranked No. 3 dragon outward Patentee after: Shanxi Hua Shang Hui Trading Co., Ltd. Address before: 100039 room 83, 105 Fuxing Road, Beijing, Haidian District Patentee before: Beijing Himalayan science and Technology Development Co Ltd |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121024 Termination date: 20170522 |
|
CF01 | Termination of patent right due to non-payment of annual fee |